Breaking News Instant updates and real-time market news.

ALGN

Align Technology

$217.56

3.93 (1.84%)

16:09
10/23/19
10/23
16:09
10/23/19
16:09

Align Technology sees repurchasing at least $100M of stock in Q4

  • 23

    Oct

ALGN Align Technology
$217.56

3.93 (1.84%)

10/07/19
LEHM
10/07/19
NO CHANGE
Target $272
LEHM
Overweight
Barclays clear aligner survey positive for Align Technology
Barclays analyst Steve Valiquette views his clear aligner survey last week to gauge U.S. trends for Q3 as positive for Align Technology. Based on the survey, the analyst believes the U.S. volume outlook looks solid, and his Align Technology revenue growth assumptions of 21% in 2019 and 23% in 2020 are unchanged. Further, respondents indicated there was no notable Invisalign discounting program in Q3 beyond the normal volume-tier discounts, Valiquette tells investors in a research note. The analyst lowered his price target for Align Technology to $272 from $300 and keeps an Overweight rating on the shares.
10/07/19
STFL
10/07/19
NO CHANGE
Target $290
STFL
Buy
Align Technology shares oversold at current levels, says Stifel
Stifel analyst Jonathan Block, who initiated coverage of SmileDirectClub (SDC) with a Buy rating and $19 price target this morning, said in a separate note to investors that he continues to view Align Technology (ALGN) as his preferred name in the clear aligner space. While challenges, such as foreign exchange headwinds and China's macro issues, remain, EMEA has been strong for the company and he "likes what he sees so far" within his proprietary U.S. due diligence, Block tells investors. He views Align shares as oversold at current levels and expects "worst case fears" around Align's share losses to SmileDirect to ease in coming quarters, Block noted. He keeps a Buy rating on Align shares with a $290 price target.
10/17/19
STFL
10/17/19
NO CHANGE
Target $290
STFL
Buy
Align Technology survey results support positive stance, says Stifel
Stifel analyst Jonathan Block said his recent survey work on Align Technology has been favorable and supports his positive stance, with providers citing "solid" Invisalign momentum at their practices, "healthy" 2020 case volume expectations, and little incremental progress from competing traditional clear aligner offerings. His checks also detected some acknowledgement of incremental Invisalign case volume resulting from Align's increased sales force investments, noted Block, who keeps a Buy rating and $290 price target on Align shares.
10/23/19
NRCS
10/23/19
NO CHANGE
Target $299
NRCS
Buy
Northcoast analysis shows favorable utilization trends for Align's Invisalign
Northcoast analyst David Keiser says that despite a more competitive clear aligner market, his North American Invisalign doctor analysis suggests favorable utilization trends have continued. 13 additional Invisalign doctors in the analyst's sample size reached the four upper tiers of Align Technology's Invisalign Advantage Program, and he also saw a sequential increase of 85 Invisalign doctors in the Silver level of the Invisalign Advantage program. Keiser maintains a Q3 earnings per share estimate of $1.16 for Align Technology, which is 2c ahead of consensus. He reiterates a Buy rating on the shares with a $299 price target.

TODAY'S FREE FLY STORIES

AMX

America Movil, also tag AMOV

$15.92

0.02 (0.13%)

, AMOV

America Movil, also tag AMX

$15.70

(0.00%)

15:46
11/11/19
11/11
15:46
11/11/19
15:46
Periodicals
Mexican regulator probing 'monopolistic' mobile phone practices, Bloomberg says »

The IFT investigative…

AMX

America Movil, also tag AMOV

$15.92

0.02 (0.13%)

AMOV

America Movil, also tag AMX

$15.70

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MNK

Mallinckrodt

$2.94

-0.165 (-5.31%)

15:37
11/11/19
11/11
15:37
11/11/19
15:37
Hot Stocks
Mallinckrodt says Phase 3 CONFIRM study met primary endpoint »

Mallinckrodt announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

FGEN

FibroGen

$35.69

-5.92 (-14.23%)

15:34
11/11/19
11/11
15:34
11/11/19
15:34
Options
FibroGen options imply 13.7% move in share price post-earnings »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Nov

FNV

Franco-Nevada

$95.70

0.09 (0.09%)

15:19
11/11/19
11/11
15:19
11/11/19
15:19
Options
Franco-Nevada options imply 4.3% move in share price post-earnings »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

MNST

Monster Beverage

$57.81

-0.38 (-0.65%)

15:17
11/11/19
11/11
15:17
11/11/19
15:17
Recommendations
Monster Beverage analyst commentary  »

Monster Beverage said to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

15:17
11/11/19
11/11
15:17
11/11/19
15:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

15:16
11/11/19
11/11
15:16
11/11/19
15:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DXC

DXC Technology

$29.63

-0.45 (-1.50%)

15:04
11/11/19
11/11
15:04
11/11/19
15:04
Options
DXC Technology options imply 23.0% move in share price post-earnings »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Nov

MRK

Merck

$83.09

-0.5 (-0.60%)

15:01
11/11/19
11/11
15:01
11/11/19
15:01
Hot Stocks
Merck reports ERVEBO vaccine granted conditional approval in EU »

Merck announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

  • 07

    Dec

  • 24

    Jan

  • 24

    Jan

  • 05

    Feb

  • 14

    Mar

BTI

British American Tobacco

$37.41

0.38 (1.03%)

, MO

Altria Group

$46.49

0.08 (0.17%)

14:51
11/11/19
11/11
14:51
11/11/19
14:51
Hot Stocks
Trump says will meet with representatives of the vaping industry »

U.S. President Donald…

BTI

British American Tobacco

$37.41

0.38 (1.03%)

MO

Altria Group

$46.49

0.08 (0.17%)

IMBBY

Imperial Brands

$0.00

(0.00%)

PM

Philip Morris

$83.70

0.11 (0.13%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

WMGI

Wright Medical

$29.39

-0.01 (-0.03%)

14:49
11/11/19
11/11
14:49
11/11/19
14:49
Options
Wright Medical options imply 3.5% move in share price post-earnings »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

COG

Cabot Oil & Gas

$17.86

-0.515 (-2.80%)

14:45
11/11/19
11/11
14:45
11/11/19
14:45
Options
Cabot Oil & Gas call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TOT

Total

$54.72

-0.08 (-0.15%)

, USO

United States Oil Fund

$11.94

-0.055 (-0.46%)

14:27
11/11/19
11/11
14:27
11/11/19
14:27
Periodicals
Total CEO sees weak oil demand growth next year, Bloomberg says »

Total CEO Patrick…

TOT

Total

$54.72

-0.08 (-0.15%)

USO

United States Oil Fund

$11.94

-0.055 (-0.46%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KMB

Kimberly-Clark

$131.12

-0.37 (-0.28%)

, ACN

Accenture

$189.95

0.34 (0.18%)

14:25
11/11/19
11/11
14:25
11/11/19
14:25
Periodicals
Kimberly-Clark moving some ad duties to Accenture from WPP, WSJ says »

Kimberly-Clark (KMB) has…

KMB

Kimberly-Clark

$131.12

-0.37 (-0.28%)

ACN

Accenture

$189.95

0.34 (0.18%)

WPP

WPP

$64.60

-0.01 (-0.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Nov

  • 19

    Nov

  • 19

    Dec

  • 23

    Jan

WPP

WPP

$64.60

-0.01 (-0.02%)

, ACN

Accenture

$190.05

0.44 (0.23%)

14:21
11/11/19
11/11
14:21
11/11/19
14:21
Periodicals
Kimberly-Clark moving some ad duties to Accenture from WPP, WSJ says »

Kimberly-Clark (KMB) has…

WPP

WPP

$64.60

-0.01 (-0.02%)

ACN

Accenture

$190.05

0.44 (0.23%)

KMB

Kimberly-Clark

$131.12

-0.37 (-0.28%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Nov

  • 19

    Nov

  • 19

    Dec

  • 23

    Jan

MS

Morgan Stanley

$49.30

0.15 (0.31%)

14:20
11/11/19
11/11
14:20
11/11/19
14:20
Options
Heavy bullish option flow in Morgan Stanley January term »

Heavy bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Nov

  • 12

    Nov

BABA

Alibaba

$186.42

-0.69 (-0.37%)

, AAPL

Apple

$261.99

1.79 (0.69%)

14:17
11/11/19
11/11
14:17
11/11/19
14:17
Hot Stocks
Alibaba reports 11.11 gross merchandise volume grew 26% year-over-year to $38.4B »

Alibaba Group (BABA)…

BABA

Alibaba

$186.42

-0.69 (-0.37%)

AAPL

Apple

$261.99

1.79 (0.69%)

EL

Estee Lauder

$186.46

-0.81 (-0.43%)

GPS

Gap

$17.01

0.32 (1.92%)

LRLCY

L'Oreal

$0.00

(0.00%)

LEVI

Levi Strauss

$17.07

-0.06 (-0.35%)

NSRGY

Nestle

$0.00

(0.00%)

NKE

Nike

$89.89

0.09 (0.10%)

VFC

VF Corp.

$86.52

-0.56 (-0.64%)

UA

Under Armour

$15.81

-0.07 (-0.44%)

UAA

Under Armour

$17.53

-0.02 (-0.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

  • 19

    Nov

  • 21

    Nov

  • 06

    Feb

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

14:17
11/11/19
11/11
14:17
11/11/19
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

14:16
11/11/19
11/11
14:16
11/11/19
14:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PCG

PG&E

$6.05

-0.42 (-6.49%)

14:13
11/11/19
11/11
14:13
11/11/19
14:13
Periodicals
CA governor raises objections to $11B PG&E insurance deal, WSJ reports »

California Governor Gavin…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

  • 07

    Jan

AUPH

Aurinia Pharmaceuticals

$5.05

-0.085 (-1.66%)

14:05
11/11/19
11/11
14:05
11/11/19
14:05
Options
Aurinia Pharmaceuticals call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

LPCN

Lipocine

$0.78

-1.945 (-71.38%)

14:04
11/11/19
11/11
14:04
11/11/19
14:04
Recommendations
Lipocine analyst commentary  »

Lipocine price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FIT

Fitbit

$6.93

-0.13 (-1.84%)

13:55
11/11/19
11/11
13:55
11/11/19
13:55
Options
Fitbit put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DB

Deutsche Bank

$7.61

-0.02 (-0.26%)

13:45
11/11/19
11/11
13:45
11/11/19
13:45
Options
Deutsche Bank call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LPCN

Lipocine

$0.82

-1.9039 (-69.87%)

13:37
11/11/19
11/11
13:37
11/11/19
13:37
Downgrade
Lipocine rating change at Ladenburg »

Lipocine downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.